Depression in ARD v1

  • Research type

    Research Study

  • Full title

    Depression and Anxiety in an Adult Patient Population with Advanced Renal Disease

  • IRAS ID

    119114

  • Contact name

    Gillian Hirst

  • Contact email

    Gillian.Hirst@cmft.nhs.uk

  • Sponsor organisation

    Central Manchester University Hospitals NHS Foundation Trust

  • Research summary

    Depression and Anxiety in an Adult Patient Population with Advanced Renal Disease.

    Depression is thought to affect from 20 to >30% of patients who suffer from Advanced (End Stage) Renal Disease (ESRD), but it is not commonly recognised or treated, and therefore there is a lack of information about how it should be treated in these patients. Recent research has highlighted the pressing need for large-scale trials to assess the effectiveness of both medication and psychosocial treatments for depression in ESRD patients. Depression is associated with poor health outcomes and reduced quality of life. Symptoms of depression such as fatigue, loss of energy, decreased appetite, and sleep disturbance are known to overlap symptoms associated with ESRD, but there are questionnaires available which provide a valid means of diagnosing depression in ESRD patients. At MRI we have large pre-dialysis (480 patients) and dialysis (595 patients) populations, consisting of patients on home haemodialysis (76 patients) and peritoneal dialysis (86 patients), as well as those who are on maintenance haemodialysis, either in the MRI unit (188 patients) or in satellite units (245 patients). We also have a group of ESRD patients (84) managed conservatively (CM) without dialysis treatment. We propose investigating the prevalence of anxiety, depression and symptoms using two self–completed questionnaires in the dialysis and CM groups. Our intention would be to include as many patients as possible to allow us to compare results from the different dialysis treatment groups. This will identify, for the first time, the extent of anxiety and depression among our patients, and whether this is associated more with one type of treatment than another. This will be the first step towards addressing this unmet clinical need.

  • REC name

    North West - Greater Manchester Central Research Ethics Committee

  • REC reference

    13/NW/0424

  • Date of REC Opinion

    19 Jul 2013

  • REC opinion

    Further Information Favourable Opinion